Lantern Pharma Granted Patent Certificate by Japanese Patent Office for LP-284 Drug Candidate's Composition of Matter
Lantern Pharma has disclosed that the Japan Patent Office (JPO) has granted a Certificate of Patent for patent concerning Lantern Pharma’s drug candidate LP-284 ((+)N-hydroxy-N-(methylacylfulvene)urea). This patent encompasses LP-284 and its novel molecular entity, reinforcing Lantern's intellectual property base. The issuance of the Certificate of Patent follows thorough examinations by the JPO, affirming the patent's merits and granting Lantern significant protective coverage. Panna Sharma, CEO and President of Lantern Pharma, expressed enthusiasm about this development, stating, “Securing a JPO-issued patent for LP-284 further solidifies its potential in the commercial sphere and underscores its promise in addressing the unmet needs of patients with non-Hodgkin’s lymphomas. This achievement also underscores the pivotal role of Lantern’s AI technologies in expediting the advancement of innovative cancer treatments.”
Lantern Pharma Granted Patent Certificate by Japanese Patent Office for LP-284 Drug Candidate's Composition of Matter